Lantheus (NASDAQ:LNTH) Reaches New 1-Year Low - Here's Why

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $73.20 and last traded at $73.76, with a volume of 113826 shares trading hands. The stock had previously closed at $75.13.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LNTH shares. Truist Financial decreased their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. B. Riley reduced their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, StockNews.com upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $132.67.

Lantheus Trading Down 1.8%

The stock has a 50-day moving average price of $95.68 and a 200 day moving average price of $92.64. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of 12.24 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. During the same quarter last year, the company earned $1.69 EPS. The firm's revenue for the quarter was up .8% on a year-over-year basis. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of the company. Kestra Investment Management LLC purchased a new position in Lantheus during the 4th quarter valued at about $27,000. Summit Securities Group LLC acquired a new stake in shares of Lantheus during the fourth quarter worth about $37,000. Signaturefd LLC boosted its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares during the period. Quarry LP grew its holdings in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock valued at $48,000 after purchasing an additional 470 shares in the last quarter. Finally, UMB Bank n.a. increased its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after buying an additional 134 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.